Capital Fund Viii, L.P. Vivo Net Worth

The estimated Net Worth of Capital Fund Viii, L.P. Vivo is at least $7.33 Million dollars as of 28 April 2017. Capital Vivo owns over 1,282,052 units of BioPharmX stock worth over $7,330,096 and over the last 8 years Capital sold BPMX stock worth over $0.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

or

Sign up with Google Sign up with Facebook

Capital Vivo BPMX stock SEC Form 4 insiders trading

Capital has made over 1 trades of the BioPharmX stock since 2017, according to the Form 4 filled with the SEC. Most recently Capital bought 1,282,052 units of BPMX stock worth $1,000,001 on 28 April 2017.

The largest trade Capital's ever made was buying 1,282,052 units of BioPharmX stock on 28 April 2017 worth over $1,000,001. On average, Capital trades about 1,282,052 units every 0 days since 2017. As of 28 April 2017 Capital still owns at least 14,096,338 units of BioPharmX stock.

You can see the complete history of Capital Vivo stock trades at the bottom of the page.

What's Capital Vivo's mailing address?

Capital's mailing address filed with the SEC is 505 HAMILTON AVENUE, SUITE 207, , PALO ALTO, CA, 94301.

Insiders trading at BioPharmX

Over the last 10 years, insiders at BioPharmX have traded over $1,425,057 worth of BioPharmX stock and bought 7,392,667 units worth $2,162,100 . The most active insiders traders include Resources Inc Franklin, Capital Viii, Llc Vivo, and Stephen Morlock. On average, BioPharmX executives and independent directors trade stock every 79 days with the average trade being worth of $308,564. The most recent stock trade was executed by Pharmaceuticals Llc Timber on 10 February 2020, trading 55,008 units of BPMX stock currently worth $550.

What does BioPharmX do?

BioPharmX Corp. is a specialty pharmaceutical company focused on developing prescription products utilizing its proprietary HyantX Topical Delivery System for dermatology indications. The HyantX delivery system is designed to stabilize and solubilize hydrophilic molecules in an anhydrous gel environment. The company was founded by James R. Pekarsky and Anja B. Krammer on August 30, 2010 and is headquartered in Campbell, CA.

Complete history of Capital Vivo stock trades at BioPharmX

BioPharmX executives and stock owners

BioPharmX executives and other stock owners filed with the SEC include:

• Lubor Gaal,
  Independent Director
• David Cohen,
  Independent Director
• Edward Sitar,
  Director
• Gianluca Pirozzi,
  Director
• Amir Tavakkol,
  Chief Scientific Officer
• Joyce Goto,
  Chief Accounting Officer
• Zachary Rome,
  Chief Operating Officer, Executive Vice President, Secretary, Director
• Joseph Lucchese,
  Chief Financial Officer, Executive Vice President
• John Koconis,
  Chief Executive Officer, Director
• Michael Derby,
  Executive Chairman of the Board
• Sciences Llc Tardi Med,
  10% owner
• Pharmaceuticals Llc Timber,
  10% owner
• David S Tierney,
  CEO
• Ronald Todd Plott,
  Director
• Stephen Morlock,
  Director
• Kin Foong Chan,
  EVP of R&D
• Anja B Krammer,
  President
• Michael Hubbard,
  Director
• Resources Inc Franklin,
  10% owner
• Capital Viii, Llc Vivo,
  10% owner
• Craig A. Barbarosh,
  Director
• Gregory David Kitchener,
  CFO
• Capital Fund Viii, L.P. Vivo,
  10% owner
• Charles Gregory Vontz,
  Director
• Steven Bosacki,
  Chief Operating Officer